Expert Opinion: Key Trials from 2024 ASCO GU
Research
This is a guest post by Dr. Arpita Desai, an oncologist at the University of California San Francisco specializing in genitourinary cancers. She summarized the results and takeaways for patients from key trials presented at the recent American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). Survival benefit seen for adjuvant pembrolizumab Over the past five decades, researchers have…
Read More